These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 32508030)

  • 1. HOTAIR-EZH2 inhibitor AC1Q3QWB upregulates CWF19L1 and enhances cell cycle inhibition of CDK4/6 inhibitor palbociclib in glioma.
    Shi J; Lv S; Wu M; Wang X; Deng Y; Li Y; Li K; Zhao H; Zhu X; Ye M
    Clin Transl Med; 2020 Jan; 10(1):182-198. PubMed ID: 32508030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Compound AC1Q3QWB Selectively Disrupts HOTAIR-Mediated Recruitment of PRC2 and Enhances Cancer Therapy of DZNep.
    Li Y; Ren Y; Wang Y; Tan Y; Wang Q; Cai J; Zhou J; Yang C; Zhao K; Yi K; Jin W; Wang L; Liu M; Yang J; Li M; Kang C
    Theranostics; 2019; 9(16):4608-4623. PubMed ID: 31367244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination LSD1 and HOTAIR-EZH2 inhibition disrupts cell cycle processes and induces apoptosis in glioblastoma cells.
    Zhao J; Jin W; Yi K; Wang Q; Zhou J; Tan Y; Xu C; Xiao M; Hong B; Xu F; Zhang K; Kang C
    Pharmacol Res; 2021 Sep; 171():105764. PubMed ID: 34246782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Compound AC1Q3QWB upregulates CDKN1A and SOX17 by interrupting the HOTAIR-EZH2 interaction and enhances the efficacy of tazemetostat in endometrial cancer.
    Chen L; Zheng X; Liu W; Sun Y; Zhao S; Tian L; Tian W; Xue F; Kang C; Wang Y
    Cancer Lett; 2023 Dec; 578():216445. PubMed ID: 37866545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined use of CDK4/6 and mTOR inhibitors induce synergistic growth arrest of diffuse intrinsic pontine glioma cells via mutual downregulation of mTORC1 activity.
    Asby DJ; Killick-Cole CL; Boulter LJ; Singleton WG; Asby CA; Wyatt MJ; Barua NU; Bienemann AS; Gill SS
    Cancer Manag Res; 2018; 10():3483-3500. PubMed ID: 30254491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CDK4/6 inhibition is more active against the glioblastoma proneural subtype.
    Li M; Xiao A; Floyd D; Olmez I; Lee J; Godlewski J; Bronisz A; Bhat KPL; Sulman EP; Nakano I; Purow B
    Oncotarget; 2017 Aug; 8(33):55319-55331. PubMed ID: 28903422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Palbociclib Effectively Halts Proliferation but Fails to Induce Senescence in Patient-Derived Glioma Stem Cells.
    Morris-Hanon O; Marazita MC; Romorini L; Isaja L; Fernandez-Espinosa DD; Sevlever GE; Scassa ME; Videla-Richardson GA
    Mol Neurobiol; 2019 Nov; 56(11):7810-7821. PubMed ID: 31124078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent anti-tumor efficacy of palbociclib in treatment-naïve H3.3K27M-mutant diffuse intrinsic pontine glioma.
    Sun Y; Sun Y; Yan K; Li Z; Xu C; Geng Y; Pan C; Chen X; Zhang L; Xi Q
    EBioMedicine; 2019 May; 43():171-179. PubMed ID: 31060906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting PEG10 as a novel therapeutic approach to overcome CDK4/6 inhibitor resistance in breast cancer.
    Katuwal NB; Kang MS; Ghosh M; Hong SD; Jeong YG; Park SM; Kim SG; Sohn J; Kim TH; Moon YW
    J Exp Clin Cancer Res; 2023 Nov; 42(1):325. PubMed ID: 38017459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic effect of palbociclib in chondrosarcoma: implication of cyclin-dependent kinase 4 as a potential target.
    Ouyang Z; Wang S; Zeng M; Li Z; Zhang Q; Wang W; Liu T
    Cell Commun Signal; 2019 Feb; 17(1):17. PubMed ID: 30808351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulating lncRNA SNHG15/CDK6/miR-627 circuit by palbociclib, overcomes temozolomide resistance and reduces M2-polarization of glioma associated microglia in glioblastoma multiforme.
    Li Z; Zhang J; Zheng H; Li C; Xiong J; Wang W; Bao H; Jin H; Liang P
    J Exp Clin Cancer Res; 2019 Aug; 38(1):380. PubMed ID: 31462285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CDK4/6 inhibitor palbociclib overcomes acquired resistance to third-generation EGFR inhibitor osimertinib in non-small cell lung cancer (NSCLC).
    Qin Q; Li X; Liang X; Zeng L; Wang J; Sun L; Zhong D
    Thorac Cancer; 2020 Sep; 11(9):2389-2397. PubMed ID: 32677256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of miRNA-3613-3p Enhances the Sensitivity of Triple Negative Breast Cancer to CDK4/6 Inhibitor Palbociclib.
    Yu Y; Liao H; Xie R; Zhang Y; Zheng R; Chen J; Zhang B
    Front Oncol; 2020; 10():590813. PubMed ID: 33330073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance.
    Martin CA; Cullinane C; Kirby L; Abuhammad S; Lelliott EJ; Waldeck K; Young RJ; Brajanovski N; Cameron DP; Walker R; Sanij E; Poortinga G; Hannan RD; Pearson RB; Hicks RJ; McArthur GA; Sheppard KE
    Int J Cancer; 2018 May; 142(10):2139-2152. PubMed ID: 29243224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic anti-cancer activity of CDK4/6 inhibitor palbociclib and dual mTOR kinase inhibitor MLN0128 in pRb-expressing ER-negative breast cancer.
    Yamamoto T; Kanaya N; Somlo G; Chen S
    Breast Cancer Res Treat; 2019 Apr; 174(3):615-625. PubMed ID: 30607633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of cyclin-dependent kinase and immune checkpoint inhibitors for the treatment of bladder cancer.
    Long Q; Ma AH; Zhang H; Cao Z; Xia R; Lin TY; Sonpavde GP; de Vere White R; Guo J; Pan CX
    Cancer Immunol Immunother; 2020 Nov; 69(11):2305-2317. PubMed ID: 32506263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft.
    Raub TJ; Wishart GN; Kulanthaivel P; Staton BA; Ajamie RT; Sawada GA; Gelbert LM; Shannon HE; Sanchez-Martinez C; De Dios A
    Drug Metab Dispos; 2015 Sep; 43(9):1360-71. PubMed ID: 26149830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined CDK4/6 and mTOR Inhibition Is Synergistic against Glioblastoma via Multiple Mechanisms.
    Olmez I; Brenneman B; Xiao A; Serbulea V; Benamar M; Zhang Y; Manigat L; Abbas T; Lee J; Nakano I; Godlewski J; Bronisz A; Abounader R; Leitinger N; Purow B
    Clin Cancer Res; 2017 Nov; 23(22):6958-6968. PubMed ID: 28814434
    [No Abstract]   [Full Text] [Related]  

  • 19. Anti-cell growth and anti-cancer stem cell activity of the CDK4/6 inhibitor palbociclib in breast cancer cells.
    Kishino E; Ogata R; Saitoh W; Koike Y; Ohta Y; Kanomata N; Kurebayashi J
    Breast Cancer; 2020 May; 27(3):415-425. PubMed ID: 31823286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro study to assess the efficacy of CDK4/6 inhibitor Palbociclib (PD-0332991) for treating canine mammary tumours.
    Schoos A; Knab VM; Gabriel C; Tripolt S; Wagner DA; Bauder B; Url A; Fux DA
    Vet Comp Oncol; 2019 Dec; 17(4):507-521. PubMed ID: 31207004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.